Lisanti Capital Growth LLC Sells 208,886 Shares of ARS Pharmaceuticals, Inc. $SPRY

Lisanti Capital Growth LLC cut its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 49.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 211,189 shares of the company’s stock after selling 208,886 shares during the period. Lisanti Capital Growth LLC owned approximately 0.21% of ARS Pharmaceuticals worth $2,122,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. CWM LLC raised its position in ARS Pharmaceuticals by 243.7% in the third quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after acquiring an additional 1,806 shares during the period. Osaic Holdings Inc. grew its stake in ARS Pharmaceuticals by 52.8% in the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after buying an additional 1,803 shares in the last quarter. Ameritas Investment Partners Inc. grew its position in shares of ARS Pharmaceuticals by 16.1% in the second quarter. Ameritas Investment Partners Inc. now owns 5,598 shares of the company’s stock valued at $98,000 after purchasing an additional 777 shares in the last quarter. RiverPark Advisors LLC purchased a new position in ARS Pharmaceuticals during the second quarter valued at approximately $100,000. Finally, BNP Paribas Financial Markets grew its position in shares of ARS Pharmaceuticals by 58.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,097 shares of the company’s stock valued at $106,000 after purchasing an additional 2,245 shares in the last quarter. Institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Stock Down 2.3%

NASDAQ SPRY opened at $9.99 on Friday. ARS Pharmaceuticals, Inc. has a 1 year low of $6.66 and a 1 year high of $18.90. The stock has a market capitalization of $987.51 million, a PE ratio of -12.33 and a beta of 0.80. The company has a debt-to-equity ratio of 1.14, a current ratio of 6.66 and a quick ratio of 6.51. The business’s 50-day moving average is $10.58 and its 200 day moving average is $11.52.

ARS Pharmaceuticals (NASDAQ:SPRY) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07). The business had revenue of $32.50 million for the quarter, compared to the consensus estimate of $28.87 million. ARS Pharmaceuticals had a negative net margin of 56.06% and a negative return on equity of 38.77%. Sell-side analysts forecast that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Analysts Set New Price Targets

SPRY has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Zacks Research lowered ARS Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday. Finally, Roth Mkm started coverage on ARS Pharmaceuticals in a report on Tuesday, November 4th. They set a “buy” rating and a $30.00 target price for the company. Four analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $33.00.

Insiders Place Their Bets

In other news, insider Justin Chakma sold 166,380 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $8.87, for a total value of $1,475,790.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Brian Dorsey sold 21,828 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $8.71, for a total transaction of $190,121.88. Following the sale, the chief operating officer directly owned 10,789 shares in the company, valued at $93,972.19. The trade was a 66.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Company insiders own 33.50% of the company’s stock.

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.